Abata Therapeutics
Joanne Tzouvalopoulos Beck serves as Chief Technical Officer at Abata Therapeutics since September 2024, with a concurrent role as a Board Member at Astria Therapeutics, Inc. since February 2019, contributing to the Compensation Committee and Science & Technology Committee. Previously, Joanne held the position of Chief Technical Officer at Aerium Therapeutics from November 2022 to July 2024 and served as a Board Member for Orchard Therapeutics from July 2018 to January 2024, also participating in key committee roles until its acquisition by Kyowa Kirin. Joanne's experience includes serving as Chief Operating Officer at Boston Pharmaceuticals from 2019 to January 2023, and interim Chief Executive Officer at Alliance for Regenerative Medicine in 2019. Earlier roles include Executive Vice President at Celgene, Senior Vice President at Shire, and various positions at AbbVie/Abbott, emphasizing pharmaceutical development and operations. Educational qualifications include a PhD in Biochemistry and Molecular Biology from Oregon Health & Science University and a BA in Chemistry from Lewis & Clark College, alongside postdoctoral training at the University of California, San Francisco.
This person is not in any teams
Abata Therapeutics
1 followers
Abata Therapeutics is bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to their lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). They bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers.